Skip to content

Study · Not a test of the peptide alone · 2015

3 results

[Triplet anti-tumor therapy based on thymosin α-1 attenuates incidence of hepatoma and serum alpha-fetoprotein level in rat hepatoma model].

Fu X, Wei Y, Zheng D, Zhou L, Zhu Z, Song J, Feng L, Du G

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology1 Jun 2015Cited by 1 (Europe PMC)

PMID26062414 (opens in a new tab)PepBankPUB-26062414
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with DEN-induced liver cancer, triple therapy with thymosin alpha‑1, Huaier granule and sirolimus gave a lower cancer incidence than single drugs.

    In plain wordsIn rats with liver cancer, a three-drug combination that included thymosin alpha‑1 gave lower cancer rates than single drugs.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLiver cancer incidence at 20 weeks
    Study

    ratn: not reported in source

    DEN-induced liver cancer
    Comparator
    Single drug treatments
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    According to the incidence rate of liver cancer and the survival rate at 20 weeks, the triple anti-tumor therapy was significantly superior to the single drug treatments.
    2 context sentences
    Summary · context
    To explore the impact of triple anti-tumor therapy based on thymosin α1 (Tα1) combined with Huaier granule(HG) and sirolimus on the level of serum alpha-fetoprotein (AFP) in rat models of liver cancer.
    Summary · context
    Except the blank control group, the rats in the other groups were induced using diethylnitrosamine (DEN) to establish liver cancer models.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with DEN-induced liver cancer, triple therapy with thymosin alpha‑1, Huaier granule and sirolimus gave a higher survival rate than single drugs.

    In plain wordsIn rats with liver cancer, a three-drug combination that included thymosin alpha‑1 gave better survival than single drugs.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival rate at 20 weeks
    Study

    ratn: not reported in source

    DEN-induced liver cancer
    Comparator
    Single drug treatments
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    According to the incidence rate of liver cancer and the survival rate at 20 weeks, the triple anti-tumor therapy was significantly superior to the single drug treatments.
    2 context sentences
    Summary · context
    To explore the impact of triple anti-tumor therapy based on thymosin α1 (Tα1) combined with Huaier granule(HG) and sirolimus on the level of serum alpha-fetoprotein (AFP) in rat models of liver cancer.
    Summary · context
    Except the blank control group, the rats in the other groups were induced using diethylnitrosamine (DEN) to establish liver cancer models.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with DEN-induced liver cancer, triple therapy with thymosin alpha‑1, Huaier granule and sirolimus lowered serum alpha-fetoprotein.

    In plain wordsIn rats with liver cancer, a three-drug combination that included thymosin alpha‑1 lowered a blood tumor marker.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum alpha-fetoprotein level
    Study

    ratn: not reported in source

    DEN-induced liver cancer
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In addition, the triple anti-tumor therapy significantly reduced the level of serum AFP in the rats.
    2 context sentences
    Summary · context
    To explore the impact of triple anti-tumor therapy based on thymosin α1 (Tα1) combined with Huaier granule(HG) and sirolimus on the level of serum alpha-fetoprotein (AFP) in rat models of liver cancer.
    Summary · context
    Except the blank control group, the rats in the other groups were induced using diethylnitrosamine (DEN) to establish liver cancer models.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.